Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ONCT

Oncternal Therapeutics (ONCT) Stock Price, News & Analysis

Oncternal Therapeutics logo

About Oncternal Therapeutics Stock (NASDAQ:ONCT)

Advanced Chart

Key Stats

Today's Range
$0.53
$0.53
50-Day Range
$0.53
$0.53
52-Week Range
$0.53
$7.17
Volume
N/A
Average Volume
99,758 shs
Market Capitalization
$1.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00
Consensus Rating
Hold

Company Overview

Receive ONCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ONCT Stock News Headlines

BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. tc pixel
Oncternal Therapeutics Reports Q3 2024 Earnings
See More Headlines

ONCT Stock Analysis - Frequently Asked Questions

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) announced its earnings results on Thursday, August, 8th. The company reported ($2.89) earnings per share for the quarter, beating the consensus estimate of ($3.03) by $0.14. The business earned $0.80 million during the quarter, compared to analysts' expectations of $0.24 million. Oncternal Therapeutics had a negative trailing twelve-month return on equity of 177.58% and a negative net margin of 1,599.95%.
Read the conference call transcript
.

Shares of Oncternal Therapeutics reverse split on Monday, January 8th 2024.The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncternal Therapeutics investors own include NIO (NIO), Walt Disney (DIS), Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META) and Moderna (MRNA).

Company Calendar

Last Earnings
8/08/2024
Today
8/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ONCT
CIK
1260990
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$2.00
Low Price Target
$2.00
Potential Upside/Downside
+279.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($11.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.48 million
Net Margins
-1,599.95%
Pretax Margin
-1,599.95%
Return on Equity
-177.58%
Return on Assets
-131.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.39
Quick Ratio
2.39

Sales & Book Value

Annual Sales
$790 thousand
Price / Sales
1.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.19 per share
Price / Book
0.05

Miscellaneous

Outstanding Shares
2,960,000
Free Float
2,628,000
Market Cap
$1.56 million
Optionable
No Data
Beta
1.18

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ONCT) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners